Background
==========

Low-grade cribriform cystadenocarcinoma (LGCCC) is a rare neoplasm of salivary gland. Originally, it was described as a variant of salivary duct carcinoma (SDC) by Delgado et al. in 1996 \[[@B1]\]. LGCCC usually occurs in elder people with a female predominance of 2:1. Parotid gland is the most common site of involvement \[[@B1]-[@B6]\]. Presentation in the palate \[[@B7]\], submandibular gland \[[@B2]\], intraparotid lymph node \[[@B2],[@B6]\] and accessory parotid gland \[[@B8]\] may occur but rare. LGCCC is characterized by the papillary-cystic or cribriform proliferation pattern and resembles the low-grade ductal carcinoma in situ or atypical ductal hyperplasia of the breast in histology and biological features. LGCCC was originally denominated as low-grade salivary duct carcinoma (LGSDC) in order to distinguish with the conventional SDC. In contrast with the LGCCC, conventional SDC exhibits highly aggressive malignancy and high-grade histology similar to an invasive ductal carcinoma of the breast. However, no definite association was found between LGCCC and conventional SDC; therefore, the third WHO classification regards this neoplasm as a variant of cystadenocarcinoma due to its cystic morphology \[[@B9]\].

Histologically, LGCCC was composed of single or multiple cystically enlarged ducts accompanied by adjacent intraductal proliferation. Various structures, such as cystic structures, loose cribriform and micropapillae pattern or solid area, could be observed in LGCCC. The typical cyst structures are lined by small or multilayered mild ductal cells with finely dispersed chromatin and small nucleoli. These tumor cells are diffusely strong positive for S100. Myoepithelial markers highlight the tumor cells rimming the cystic spaces, confirming the intraductal nature of LGCCC. Based on the histological features, LGCCC should be distinguished with other common parotid tumors including papillocystic variant of acinic cell carcinoma (PCV-ACC), conventional SDC, cystadenocarcinoma, polymorphous low-grade adenocarcinoma (PLGA), carcinoma ex pleomorphic adenoma and mammary analogue secretory carcinoma (MASC).

Case presentation
=================

Clinical history
----------------

### Case 1

A 48-year-old male was admitted to the First Affiliated Hospital of China Medical University in August of 2011 for further examination because of the mass in the left parotid region. The mass was soft, non-tender and did not adhere to the skin. Ultrasound examination revealed a nonhomogenous hypoechogenic mass with anechogenic areas measuring 21×12 mm. Examination by fine needle aspiration cytology was not performed. The patient underwent parotidectomy without radiotherapy. The patient was alive with no tumor recurrence or metastasis at 16 months of follow-up.

### Gross features

The surgical specimen measured 3.5 cm in the greatest diameter. On cut surface, it showed a nonencapsulated tumor measured 2×1 cm. The tumor was whitish in color.

### Microscopic features

The tumor was demarcated from the surrounding slightly lipomatous parotid glands with a relative boundary (Figure [1](#F1){ref-type="fig"}A and B). The lesion was dominated by a large cystic space with multiple small well demarcated tumor islets in the fibrous stroma close to the central cyst. The architecture of these islets varied from solid (Figure [1](#F1){ref-type="fig"}C) to cribriform and micropapillary (Figure [1](#F1){ref-type="fig"}D). Within the lumen, pink secretions could be observed, but no comedo necrosis was identified. The tumor cells were uniform without significant cytologic and nuclear atypia. They displayed round to oval nuclei with fine chromatin and prominent nucleoli and pale to amphophilic cytoplasm. Apocrine differentiation of tumor cells was not obvious. No atypical mitosis was observed.

![**Histological features and immunohistochemical staining of both cases. A**-**B**: Case 1, the tumor was demarcated from the surrounding slightly lipomatous parotid glands with a relative boundary. **C**-**D**: Case 1, within the tumor, solid and micropapillary pattern were observed. **E**-**F**: Case 2, the tumor was demarcated from the surrounding parotid glands with a clear boundary. **G**: Case 2, the tumor cells were uniform without significant cytologic and nuclear atypia. They displayed round to oval nuclei with fine chromatin and pale to amphophilic cytoplasm. **H**: Case 2, Apocrine differentiation of tumor cells was observed focally. **I**: The luminal tumor cells showed diffusive expression of S100 (Case 1 and 2). **J**: Immunostaining for p63 displayed a continuous rim of myoepithelial cells around all tumor islets (Case 1 and 2).](1746-1596-8-28-1){#F1}

### Immunohistochemistry

Immunohistochemically, the luminal tumor cells showed diffuse expression of CK and S100 (Figure [1](#F1){ref-type="fig"}I). Immunostaining for p63 (Figure [1](#F1){ref-type="fig"}J) and SMA displayed a continuous rim of myoepithelial cells around all tumor islets. No myoepithelial cells were admixed with the luminal cells. Tumor cells were negative for CEA, AR, ER, PR, EGFR, and Her-2/neu oncoprotein. Ki67 index was less than 5%.

### Case 2

A 59-year-old female was admitted to the First Affiliated Hospital of China Medical University in May of 2012 for further examination because of the mass in the right parotid region. The physical examination showed a solid mass in the right parotid with slight tender and the mass did not adhere to the skin. Ultrasound examination revealed a homogenous hypoechogenic mass measuring 35×21×22 mm. Examination by fine needle aspiration cytology was not performed. The patient underwent parotidectomy without radiotherapy. The patient was alive with no tumor recurrence or metastasis at 7 months of follow-up.

### Gross features

The surgical specimen measured 4 cm in the greatest diameter. On cut surface, it showed a well-circumscribed tumor measured 3×2 cm. The tumor was whitish in color.

### Microscopic features

The tumor was demarcated from the surrounding parotid glands with a clear boundary (Figure [1](#F1){ref-type="fig"}E and F). The lesion was mainly composed of solid to cribriform and micropapillary structures, while the dilated cystic structures were rarely seen. No comedo necrosis was identified. The tumor cells were uniform without significant cytologic and nuclear atypia. They displayed round to oval nuclei with fine chromatin and pale to amphophilic cytoplasm (Figure [1](#F1){ref-type="fig"}G). Apocrine differentiation of tumor cells was observed locally (Figure [1](#F1){ref-type="fig"}H). No atypical mitosis was observed.

### Immunohistochemistry

Immunohistochemically, the luminal tumor cells showed diffuse expression of CK, CK7 and S100 (Figure [1](#F1){ref-type="fig"}I). Immunostaining for p63 (Figure [1](#F1){ref-type="fig"}J) and smooth muscle actin (SMA) displayed a continuous rim of myoepithelial cells around all tumor islets. No myoepithelial cells were admixed with the luminal cells. Tumor cells were negative for CK20, AR, ER, PR, EGFR, and Her-2/neu oncoprotein. Ki67 index was less than 5%.

Discussion
==========

Like other rare tumors in parotid glands, LGCCC is a low-grade malignant tumor with indolent clinical behavior \[[@B10]-[@B12]\]. In the third WHO classification, it is listed under a separate heading although regarding as a variant of cystadenocarcinoma \[[@B9]\]. To date, there are nine papers totally reported 35 cases of LGCCC. The reported cases and the two cases in this paper were summarized in Table [1](#T1){ref-type="table"}. In these patients, the majority of LGCCC occurred in older patients (median 62 years) without obvious gender preponderance (Male: Female=15:21; one case with gender unavailable) though the third WHO classification described that the tumor had a female predominance. Among the cases listed in Table [1](#T1){ref-type="table"}, thirty-five tumors arose from parotid glands both in the superficial and deep lobes, including three cases occurred in the intraparotid lymph node and one occurred in accessory parotid gland. The remaining two tumors arose in the palate and submandibular gland. Therefore, all the LGCCCs reported by now occurred in large salivary glands except one controversial report on hard palate. The tumor size varied from 0.9 to 4 cm. Among the cases with follow-up available, no one had recurrence or died because of the tumor. According the clinically indolent behavior, most of the cases were treated with parotidectomy without radiotherapy.

###### 

Reported cases of the low-grade cribriform cystadenocarcinoma in the English-Language Literature and their prognosis

  **Case**   **Authors**                       **Age**   **Sex**                        **Location**                                                         **Size**        **Treatment**                                                      **Follow-up**
  ---------- --------------------------------- --------- ------------------------------ -------------------------------------------------------------------- --------------- ------------------------------------------------------------------ ---------------
  1          Delgado *et al*. 1996             58        M                              Parotid (superficial lobe)                                           1 cm            Superficial parotidectomy                                          not mentioned
  2                                            62        F                              Parotid                                                              0.7 cm          Parotidectomy                                                      not mentioned
  3                                            32        F                              Right parotid (superficial lobe)                                     1.1 cm          Parotidectomy, radiotherapy                                        NED, 144 mos
  4                                            63        M                              Right parotid (superficial lobe)                                     1.3 cm          Parotidectomy                                                      NED, 132 mos
  5                                            74        M                              Left parotid                                                         1.8 cm          Parotidectomy                                                      NED, 72 mos
  6                                            56        F                              Right parotid                                                        1 cm            Parotidectomy                                                      NED, 24 mos
  7                                            42        M                              Left parotid (superficial lobe)                                      1.2 cm          Parotidectomy                                                      NED, 24 mos
  8                                            69        F                              Right parotid (intraparotid lymph node)                              4 cm            Parotidectomy                                                      NED, 24 mos
  9                                            69        M                              Left parotid                                                         0.9 cm          Parotidectomy                                                      \-
  10                                           52        F                              Right parotid (deep lobe)                                            0.8 cm          Parotidectomy, radiotherapy                                        NED, 9 mos
  11         Tatemoto *et al*. 1996            58        F                              Palate                                                               1 cm            Not mentioned                                                      NED, 30 mos
  12         Brandwein-Gensler *et al*. 2004   62        F 8 cases M 7 cases U 1 case   Parotid 15 cases (including one case from intraparotid lymph node)   Not mentioned   Not mentioned                                                      NED, 12 mos
  13                                           82        NED, 44 mos                                                                                                                                                                            
  14                                           78        NED, 17 mos                                                                                                                                                                            
  15                                           72        NED, 108 mos                                                                                                                                                                           
  16                                           93        NED, 24 mos                                                                                                                                                                            
  17                                                     NED, 30 mos                                                                                                                                                                            
  18                                                     NED, 62 mos                                                                                                                                                                            
  19                                           64        Submandibular gland 1 case     NED, 33 mos                                                                                                                                             
  20                                           66        Not mentioned                                                                                                                                                                          
  21                                           57        NED, 30 mos                                                                                                                                                                            
  22                                           63        Not mentioned                                                                                                                                                                          
  23                                           64        NED, 6 mos                                                                                                                                                                             
  24                                           62        NED, 132 mos                                                                                                                                                                           
  25                                           72        NED, 40 mos                                                                                                                                                                            
  26                                           76        NED, 24 mos                                                                                                                                                                            
  27                                           54        Not mentioned                                                                                                                                                                          
  28         Weinreb *et al*. 2006             50        F                              Right parotid                                                        2 cm            Superficial parotidectomy                                          NED, 5 mos
  29                                           73        M                              Left parotid                                                         1.8 cm          Superficial parotidectomy and supraomohyoid neck dissection        NED, 60 mos
  30                                           67        F                              Right parotid                                                        2.5 cm          Right total parotidectomy and chemotherapy and radiation therapy   Not mentioned
  31         Arai *et al*. 2009                32        F                              Right parotid                                                        2.8 cm          Right partial parotidectomy                                        NED, 24 mos
  32         Laco *et al*. 2010                50        F                              Right parotideomasseteric area                                       1.5 cm          Enucleation of the tumor                                           NED, 24 mos
  33         Nakatsuka *et al*. 2011           27        M                              Accessory parotid gland                                              1.5 cm          Local excision of the tumor                                        NED, 3 mos
  34                                           56        F                              Left parotid                                                         3 cm            Parotidectomy                                                      NED, 12 mos
  35         Weinreb *et al*. 2011             59        F                              Left parotid (intraparotid lymph node)                               3.5 cm          Not mentioned                                                      Not mentioned
  36         Current case                      48        M                              Left parotid                                                         2cm             Parotidectomy                                                      NED, 16 mos
  37         Current case                      59        F                              Right parotid                                                        3.5 cm          Parotidectomy                                                      NED, 7 mos

*M*male; *F*female; *U*gender unavailable; *NED* no evidence of disease; *mos*months.

Grossly, the clinical suggestion of LGCCC is used to be Warthin tumor according to the morphologic feature, that is, a slowly growing cystic mass. Histologically, the tumor is unencapsulated and composed of single or multiple cysts with an intraductal proliferation. The cystic cavity is in line with cytologically bland ductal cells. The intraductal proliferation has a cribriform pattern with "sieve-like spaces" similar to breast proliferations. The majority of the tumor is intraductal; however, small areas of invasion may be present. A total of 7/37 (19%) cases summarized in Table [1](#T1){ref-type="table"} have focal stromal invasion. The tumor cells usually display little cytologic atypia and low mitotic rate \[[@B9]\]. Sometimes, the tumor cells have PAS-positive/diastase-resistant microvacuoles and yellow-brown, lipofuscin-like pigment. There is often associated hemorrhage, cholesterol clefts and hemosiderin-laden macrophages due to cyst rupture, while vascular and/or perineural invasion and comedonecrosis is absent in this tumor.

Immunohistochemically, LGCCC is characterized by diffusely strong positive for S100. However, Weinreb *et al*. \[[@B13]\] and Arai *et al*. \[[@B3]\] reported two cases of LGCCC with rarely negative for S100. All tumors examined for Her-2/neu oncoprotein, including our case, were negative. Most of the tumor structures have continuous myoepithelial rim confirmed by detection of myoepithelial markers, such as, CK5/6, CK14, SMA, and p63, thus clarifying an in situ nature of the neoplasm. Typically, admixture of luminal and myoepithelial cells is absent.

The differential diagnosis of LGCCC includes PCV-ACC, conventional SDC, cystadenocarcinoma, PLGA, carcinoma ex pleomorphic adenoma and MASC. PCV-ACC resembles LGCCC according to the intracytoplasmic PAS-positive/diastase-resistant granules (zymogen) and hemosiderin \[[@B14]\]. In contrast to LGCCC, the more common microcystic growth pattern in PCV-ACC is usually seen adjacent to cystopapillary areas and display granular basophilic cytoplasm. PCV-ACC does not exhibit predominance of the intraductal component in histology and the intracytoplasmic vacuoles are uniform in size. Compared with LGCCC, PCV-ACC is predominantly negative (about 90%) for S100 and focally expressed if present \[[@B9]\]. In addition, PCV-ACC mainly occurs in young people, while LGCCC usually affects older people.

Conventional SDC is a high-grade adenocarcinoma that is common in elder people over 50 years of age \[[@B9]\]. Histologically, SDC resembles a high-grade invasive ductal carcinoma of the breast, frequently accompanied by comedo necrosis and cribriform proliferation \[[@B9]\]. SDC exhibits an apocrine-like appearance with positivity for GCDFP-15 and androgen receptor, which is occasionally observed in LGCCC, but SDC is negative for S-100. In addition, SDC usually exhibits a high Ki-67 labeling index. Occasional cases of SDC in situ (SDCIS) have been described \[[@B15]-[@B17]\]. The in situ--like appearance or noninvasive cribriform growth pattern make it hard to distinguish between SDCIS and LGCCC. In contrast to LGCCC, the atypical cells in SDCIS exhibit high nuclear pleomorphism and AR-positive/S100-negative profile. Weinreb *et al*. \[[@B6]\] reported a series of 3 intraductal neoplasms interpreted as LGCCC with some nuclear atypia of the tumor cells, all expressing AR and in 2 cases also showing S100 expression. Thus, they consider their LGCCC cases to be a low-grade variant of SDC with a potential for transformation into a high-grade carcinoma. At present, the relationship between LGCCC and SDCIS remains unclear although the current WHO classification considering LGCCC as a variant of cystadenocarcinoma. LGCCC may be either a separate entity based on distinctive immunohistochemical profile or an extremely low-grade end of the spectrum of SDCIS.

Recently, a new entity in the salivary gland called MASC has been described \[[@B18],[@B19]\], which shows a similar microvacuolar appearance to LGCCC and may have any of solid, cystic and papillary architectures. Similar to LGCCC, MASC is also positive for S100. All these characteristics make it difficult to distinguish between LGCCC and MASC. Although no cases of MASC with an intraductal growth pattern have been described, it should be noted that only one IDC/LGCCC was included in the control group tested for the ETV6-NTRK3 fusion in Skalova et al's original description of MASC. For now, the presence of a complete myoepithelial layer around tumor nests is considered specific to LGCCC instead of MASC.

In the current WHO classification, LGCCC is regard as a variant of cystadenocarcinoma according to the histological features. However, conventional cystadenocarcinoma tends to be an invasive tumor and lacks the overall resemblance to intraductal breast proliferation. PLGA and carcinoma ex pleomorphic adenoma should also be considered when rendering a diagnosis of LGCCC. PLGA can be distinguished from LGCCC by its distinctive neurotropism and infiltrative lobular, trabecular, and tubular patterns. The transition from myoepithelium to stromal spindle cell and myxoid or cartilaginous stroma is the typical features of carcinoma ex pleomorphic adenoma, which is not observed in LGCCC.

Both of the cases exhibited the typical features of LGCCC, that is, intraductal proliferation and bland ductal cells arranged in a cribriform pattern whichresembled the low-grade breast lesions. Most of the tumor nests or cribriform structures in these two cases were rimming by the continuous myoepithelialium which confirmed by p63, thus, clarify an in situ nature of the neoplasm. The tumor cells in both cases were diffusely strong positive for S100. In addition, the Ki67 index in our cases was under 5%. All these findings supported the diagnosis of LGCCC, although the dilated cystic structures were not observed in Case 2.

Conclusion
==========

Our report illustrated two cases of LGCCC which was a rare salivary tumor. LGCCC should be considered in the differential diagnosis of salivary tumors to avoid rendering a wrong diagnosis of other highly aggressive malignant tumor of salivary gland.
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